Logo image of EDT.CA

SPECTRAL MEDICAL INC (EDT.CA) Stock Fundamental Analysis

TSX:EDT - Toronto Stock Exchange - CA8475771033 - Common Stock - Currency: CAD

0.83  -0.02 (-2.35%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to EDT. EDT was compared to 24 industry peers in the Biotechnology industry. EDT has a bad profitability rating. Also its financial health evaluation is rather negative. EDT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EDT has reported negative net income.
In the past year EDT has reported a negative cash flow from operations.
EDT had negative earnings in each of the past 5 years.
In the past 5 years EDT always reported negative operating cash flow.
EDT.CA Yearly Net Income VS EBIT VS OCF VS FCFEDT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of EDT (-289.53%) is worse than 70.83% of its industry peers.
Industry RankSector Rank
ROA -289.53%
ROE N/A
ROIC N/A
ROA(3y)-227.94%
ROA(5y)-174.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EDT.CA Yearly ROA, ROE, ROICEDT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

With a decent Gross Margin value of 44.53%, EDT is doing good in the industry, outperforming 70.83% of the companies in the same industry.
In the last couple of years the Gross Margin of EDT has declined.
The Profit Margin and Operating Margin are not available for EDT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.21%
GM growth 5Y-10.46%
EDT.CA Yearly Profit, Operating, Gross MarginsEDT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

EDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EDT has been increased compared to 1 year ago.
The number of shares outstanding for EDT has been increased compared to 5 years ago.
Compared to 1 year ago, EDT has a worse debt to assets ratio.
EDT.CA Yearly Shares OutstandingEDT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
EDT.CA Yearly Total Debt VS Total AssetsEDT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

EDT has an Altman-Z score of -44.93. This is a bad value and indicates that EDT is not financially healthy and even has some risk of bankruptcy.
EDT has a Altman-Z score of -44.93. This is in the lower half of the industry: EDT underperforms 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44.93
ROIC/WACCN/A
WACC8.32%
EDT.CA Yearly LT Debt VS Equity VS FCFEDT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

2.3 Liquidity

A Current Ratio of 0.16 indicates that EDT may have some problems paying its short term obligations.
EDT's Current ratio of 0.16 is on the low side compared to the rest of the industry. EDT is outperformed by 70.83% of its industry peers.
A Quick Ratio of 0.15 indicates that EDT may have some problems paying its short term obligations.
The Quick ratio of EDT (0.15) is worse than 70.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.15
EDT.CA Yearly Current Assets VS Current LiabilitesEDT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

EDT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.70%.
Looking at the last year, EDT shows a decrease in Revenue. The Revenue has decreased by -4.31% in the last year.
The Revenue for EDT have been decreasing by -16.08% on average. This is quite bad
EPS 1Y (TTM)-42.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.2%
Revenue 1Y (TTM)-4.31%
Revenue growth 3Y-8.7%
Revenue growth 5Y-16.08%
Sales Q2Q%-18.61%

3.2 Future

EDT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.21% yearly.
EDT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.82% yearly.
EPS Next Y-23.87%
EPS Next 2Y21.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year23.53%
Revenue Next 2Y18.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EDT.CA Yearly Revenue VS EstimatesEDT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
EDT.CA Yearly EPS VS EstimatesEDT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 -0.02 -0.04 -0.06 -0.08

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EDT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDT.CA Price Earnings VS Forward Price EarningsEDT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDT.CA Per share dataEDT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08

4.3 Compensation for Growth

A more expensive valuation may be justified as EDT's earnings are expected to grow with 21.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.21%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

EDT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPECTRAL MEDICAL INC

TSX:EDT (5/30/2025, 7:00:00 PM)

0.83

-0.02 (-2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-07 2025-08-07
Inst Owners0.04%
Inst Owner ChangeN/A
Ins Owners1.4%
Ins Owner ChangeN/A
Market Cap236.65M
Analysts84
Price Target2.35 (183.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15%
PT rev (3m)15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 103.52
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS-0.1
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -289.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.53%
FCFM N/A
ROA(3y)-227.94%
ROA(5y)-174.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.21%
GM growth 5Y-10.46%
F-Score5
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.76%
Cap/Sales 1.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.15
Altman-Z -44.93
F-Score5
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)35.44%
Cap/Depr(5y)73.91%
Cap/Sales(3y)4.85%
Cap/Sales(5y)10.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.2%
EPS Next Y-23.87%
EPS Next 2Y21.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.31%
Revenue growth 3Y-8.7%
Revenue growth 5Y-16.08%
Sales Q2Q%-18.61%
Revenue Next Year23.53%
Revenue Next 2Y18.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.75%
OCF growth 3YN/A
OCF growth 5YN/A